FairJourney Bio delivers antibody engineering for novel tumor-conditional IL-12 therapeutic approach that unlocks the potential of localized cytokine activation
FairJourney Bio ("FJBio"), a global antibody discovery expert, today announced the publication of a peer-reviewed study in mAbs describing a novel approach with the potential to improve the therapeutic window of IL-12, a potent anti-tumor cytokine.
